Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients
暂无分享,去创建一个
Roberto Tagliaferri | Francesco Iorio | Antonio Eleuteri | Kenneth Hess | Lajos Pusztai | Massimo Cristofanilli | James M. Reuben | R. Tagliaferri | K. Hess | G. Hortobagyi | L. Pusztai | F. Iorio | A. Giordano | J. Reuben | A. Eleuteri | M. Cristofanilli | Gabriel N. Hortobagyi | Antonio Giordano | Mario Giuliano | M. Giuliano | Michelino De Laurentiis | Sabino De Placido | S. Placido | M. Laurentiis
[1] T. Fehm,et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial , 2010, Breast Cancer Research and Treatment.
[2] X. Pivot,et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Goldhirsch,et al. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer , 2010, Breast Cancer Research and Treatment.
[5] M. Loda,et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer , 2010, British Journal of Cancer.
[6] T. Fehm,et al. Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.
[7] T. Fehm,et al. Information from CTC measurements for metastatic breast cancer prognosis—we should do more than selecting an “optimal cut point” , 2010, Breast Cancer Research and Treatment.
[8] T. Fehm,et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells , 2009, Breast Cancer Research.
[9] Annibale Biggeri,et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients , 2009, Breast Cancer Research and Treatment.
[10] G. Hortobagyi,et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Kristine Broglio,et al. Circulating tumor cells in metastatic breast cancer , 2008, Cancer.
[12] Antonio Eleuteri,et al. Artificial neural networks estimating survival probability after treatment of choroidal melanoma. , 2008, Ophthalmology.
[13] P.J.G. Lisboa,et al. Continuous and Discrete Time Survival Analysis: Neural Network Approaches , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[14] Leon W M M Terstappen,et al. Statistical considerations for enumeration of circulating tumor cells , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[15] F. Cognetti,et al. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend , 2007, Current opinion in obstetrics & gynecology.
[16] Brigitte Rack,et al. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.
[17] Leon W.M.M. Terstappen,et al. Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer , 2006, Clinical Cancer Research.
[18] G. T. Budd,et al. Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.
[19] Douglas G Altman,et al. Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.
[20] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Alison Stopeck,et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Regitnig,et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. , 2005, Oncology Report.
[23] D. Mavroudis,et al. Trastuzumab Administration Can Effectively Target Chemotherapy-Resistant Cytokeratin-19 Messenger RNA–Positive Tumor Cells in the Peripheral Blood and Bone Marrow of Patients With Breast Cancer , 2004, Clinical Cancer Research.
[24] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[25] Tanja Fehm,et al. HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[26] Lionel Tarassenko,et al. Non‐linear survival analysis using neural networks , 2004, Statistics in medicine.
[27] Roberto Tagliaferri,et al. A novel neural network-based survival analysis model , 2003, Neural Networks.
[28] W. Vach,et al. On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology. , 2000, Statistics in medicine.
[29] E Biganzoli,et al. Feed forward neural networks for the analysis of censored survival data: a partial logistic regression approach. , 1998, Statistics in medicine.
[30] E. Baráth,et al. Fundamentals of Biostatistics. , 1992 .
[31] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[32] G. Hortobagyi,et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] V. Valero,et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.